

UBA7 RABBIT PAB

货号: S212066

产品全名: UBA7 兔多抗

基因符号: D8; UBE2; UBA1B; UBE1L

UNIPROT ID: P41226 (Gene Accession - BC006378)

背景: The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E1 ubiquitin-activating enzyme family. The encoded enzyme is a retinoid target that triggers promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARalpha) degradation and apoptosis in acute promyelocytic leukemia, where it is involved in the conjugation of the ubiquitin-like interferon-stimulated gene 15 protein.

抗原: Fusion protein of human UBA7

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 30-150; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling, Cancer, Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human lung cancer tissue using 212066(UBA7 Antibody) at a dilution of 1/35(Nucleus and Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human lung cancer tissue is first treated with the fusion protein and then with 212066(Anti-UBA7 Antibody) at dilution 1/35.



The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using 212066(Anti-UBA7 Antibody) at a dilution of 1/35.



In comparison with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D124149(Anti-UBA7 Antibody) at dilution 1/35.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
